SNA-11 is under clinical development by SyneuRx International (Taiwan) and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNA-11’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNA-11 overview
SNA-11 is under development for the treatment of treatment resistant depression. The drug candidate acts by targeting glycine binding site of NMDA receptor.
See Also:
SyneuRx International (Taiwan) overview
SyneuRx International (Taiwan) (SyneuRx International) is a bio-medical company that specializes in developing drugs for the treatment of central nervous system-related disorders. The company is headquartered in Taipei City, Taipei, Taiwan.
For a complete picture of SNA-11’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.